Oral ketamine augmentation for chronic suicidality in treatment-resistant depression

Australian and New Zealand Journal of Psychiatry

Volumn 48, Issue 7, 2014, Pages 686-

  De Gioannis, Angelo ^a   De Leo, Diego ^a  

^a GRIFFITH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; KETAMINE; QUETIAPINE; VENLAFAXINE; ANESTHETIC AGENT; ANTIDEPRESSANT AGENT;

ADD ON THERAPY; ADULT; BIPOLAR DEPRESSION; CASE REPORT; CHRONIC PAIN; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG EFFICACY; FEMALE; HUMAN; LETTER; MALE; MENTAL HEALTH; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MULTIPLE CYCLE TREATMENT; PSYCHOPHARMACOTHERAPY; REMISSION; SUICIDAL IDEATION; TREATMENT RESISTANT DEPRESSION; TREATMENT RESPONSE; CHRONIC DISEASE; COMBINATION DRUG THERAPY; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; DRUG POTENTIATION; ORAL DRUG ADMINISTRATION; PSYCHOLOGY;

ADMINISTRATION, ORAL; ADULT; ANESTHETICS, DISSOCIATIVE; ANTIDEPRESSIVE AGENTS; CHRONIC DISEASE; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; KETAMINE; MALE; SUICIDAL IDEATION;

EID: 84903543431     PISSN: 00048674     EISSN: 14401614     Source Type: Journal    
DOI: 10.1177/0004867414520754     Document Type: Letter

References (1)

1. Katalinic N, Lai R, Somogyi A, et al. Ketamine as a new treatment for depression: A review of its efficacy and adverse effects. Australian and New Zealand Journal of Psychiatry. 2013 ; 47: 710-727